Correspondence regarding the paper “Laorden D, Zamarrón E, Romero D, Domínguez-Ortega J, Villamañán E, Losantos I, Gayá F, Quirce S, Álvarez-Sala R. Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R. Respir. Med. 2023; 211: 107216”

Abstract

[EN] We have read with great interest the recent study by Laorden et al., “Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R”. While their study provides valuable insights into using the FEOS score proposed by Perez de Llano et al. and super-responder criteria defined by Upham et al., some points require further analysis. Recently, we presented for the first time a classification of patients into the four groups of maximal improvement of FEOS proposed by Perez de Llano et al. depending on baseline conditions. One aspect worth highlighting is the differences observed in the FEOS scores reported in our study and those presented in Laorden et al